A new approach to mental health

Latest COMPASS News

Navigating Mental Health: COMPASS Pathways’ Psilocybin Research Program

Article written for the MAPS Bulletin Winter 2018, by Ekaterina Malievskaia, MD, MSc, Chief Medical Officer and Co-Founder of COMPASS Pathways

COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-resistant Depression

“This is great news for patients. The FDA will be working closely with us to expedite the development process.” George Goldsmith

COMPASS Pathways receives FDA approval for psilocybin therapy clinical trial for treatment-resistant depression

Regulatory approvals for the trial have already been given in the UK, the Netherlands and Canada.

See more company news

About us

COMPASS Pathways is a life sciences company
dedicated to accelerating patient access to evidence-based
innovation in mental health

Find out more

COMPASS team

Making a positive difference to patient experience and
mental health outcomes requires collaboration across
disciplines

Members

Research and clinical trials

We are motivated by the need to find better ways to treat and
empower patients suffering with mental illness

Research & trials

News and views

Our collective understanding of mental health is increasing
all the time, with advances in neuroscience, psychotherapy,
psychopharmacology, and digital platforms

News & views

Our mission is to accelerate patient access to innovation in mental health

Contact us